Treatment of Meniere's Disease With Migraine Medications

• Status: Recruiting
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Meniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Irvine
• Treatments: Nortriptyline; Topiramate

Criteria

Inclusion Criteria:

1. Patients with active or frequent Meniere's Disease.

2. Male or female between the ages of 25 to 85 years.

3. Subject must be compliant with the medication and attend study visits.

4. Must be able to read and write in the English language to provide consenting.

Exclusion Criteria:

1. Pregnancy will result in automatic exclusion from the study. A urine pregnancy test to rule out pregnancy for all women who are of childbearing potential.

2. Subjects with history of surgery for Meniere's Disease.

3. Subject with history of an adverse reaction to medication being prescribed.

4. Subject suffers from a medical condition or has history that may be concerning to the investigator's clinical opinion.

5. Subjects with psychosis.

6. Subjects with neurological neoplasm.

7. All contraindications for the medications which prevent subjects from randomization will be considered as exclusion criteria.